Evidence for the locations of distinct steroid and Vinca alkaloid interaction domains within the murine mdr1b P-glycoprotein

被引:14
作者
Gruol, DJ [1 ]
King, MN
Kuehne, ME
机构
[1] Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA
[2] Univ Vermont, Dept Chem, Burlington, VT 05405 USA
关键词
D O I
10.1124/mol.62.5.1238
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoproteins (P-gp) cause the efflux of a wide variety of unrelated hydrophobic compounds out of cells. However, the locations of the sites at which different classes of molecules initially interact with the protein are not well defined. A unique system was developed to search for P-gp drug-interaction domains using mutational analysis. The strategy is based upon identifying mutations that cause a decrease in the activity of P-gp inhibitors, which are structurally related to chemotherapeutic drugs transported by P-gps. Evidence of distinct steroid and taxane interaction domains has already been presented. The work reported here extends the study of the steroid interaction domain and presents evidence for a separate vinblastine interaction domain. A total of 10 steroid-related mutations, involving seven amino acids that are confined within transmembrane segments (TMS) 4 to 6, have been characterized. The location of these mutations indicates that steroids interact with the transporter within the inner leaflet of the plasma membrane. Four previously unidentified, Vinca-related mutations, involving three amino acids, have also been found. Unexpectedly, these mutations are clustered within an eight-amino acid segment proximal to the TMS-4 region. This portion of the protein is thought to be within the cytoplasmic compartment of the cell. Thus, the results suggest that at least part of the initial interaction between P-gp and Vinca alkaloids occurs in the cytoplasm. The steroid interaction domain does not extend into this region of the protein. However, this cytoplasmic section of the protein is likely to play an important role in promoting steroid transport.
引用
收藏
页码:1238 / 1248
页数:11
相关论文
共 43 条
[11]   Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein [J].
Dey, S ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM ;
Ambudkar, SV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10594-10599
[12]   Mechanism of action of p-glycoprotein in relation to passive membrane permeation [J].
Eytan, GD ;
Kuchel, PW .
INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 190, 1999, 190 :175-250
[13]   ALLOSTERIC REGULATION OF [H-3] VINBLASTINE BINDING TO P-GLYCOPROTEIN OF MCF-7 ADR CELLS BY DEXNIGULDIPINE [J].
FERRY, DR ;
MALKHANDI, PJ ;
RUSSELL, MA ;
KERR, DJ .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (12) :1851-1861
[14]   Multidrug resistance in cancer: Role of ATP-dependent transporters [J].
Gottesman, MM ;
Fojo, T ;
Bates, SE .
NATURE REVIEWS CANCER, 2002, 2 (01) :48-58
[15]  
GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394
[16]  
GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417
[17]  
GRUOL DJ, 1994, CANCER RES, V54, P3088
[18]  
Gruol DJ, 1997, CANCER RES, V57, P720
[19]   The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel [J].
Gruol, DJ ;
Bernd, J ;
Phippard, AE ;
Ojima, I ;
Bernacki, RJ .
MOLECULAR PHARMACOLOGY, 2001, 60 (01) :104-113
[20]   Profound differences in the transport of steroids by two mouse β-glycoproteins [J].
Gruol, DJ ;
Vo, QD ;
Zee, MC .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (07) :1191-1199